Hoth Therapeutics Inc (HOTH)

$1.36 +0.65 (92.01%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	26.01M
Revenue (ttm)	0.00
Net Income (ttm)	-12.47M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	165,804,703
Avg Vol	6,567,068
Day's Range	N/A - N/A
Shares Out	19.13M
Stochastic %K	81%
Beta	0.57
Analysts	Strong Sell
Price Target	$4.50

Company Profile

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs in the United States. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic...

Industry: Biotechnology

Sector: Healthcare

Phone: 866 239 7459

Website: hoththerapeutics.com

Address:

720 Monroe Street, Suite E514, Hoboken, United States

Rocket One Expands AI Infrastructure Platform Through Strategic Partnership with Placeve to Advance Defense, Space, and Intelligent Edge Computing

Rocket One adds the SpaceXAI API to its AI tech stack

2026-07-09T12:35:32.000Z - 4 weeks ago

Rocket One Reports Approximately $8.4 Million in Cash and Cash Equivalents and Outlines Strategy Across AI Infrastructure, Spintronic Computing for Space and Defense Markets

These space stocks are not SpaceX—but they're blasting off this week in the wake of IPO fever

Jun 12, 2026, 11:52 AM EDT - 2 months ago

Hoth Therapeutics Becomes Rocket One Inc. (Nasdaq: RKTO), Targeting the Space Economy with Next-Generation Nanomagnetic AI Chip Technology and Ultra-Low-Power, Radiation-Tolerant Computing for Space and Defense Applications

Jun 29, 2022, 1:25 PM EDT - 4 years ago

Hoth Therapeutics Granted 180 Day Extension by Nasdaq to Regain Compliance with Bid Price Rule

Jun 15, 2020, 8:48 AM EDT - 6 years ago

Hoth Therapeutics' Scientific Advisory Board Member and Inventor of Licensed Novel Peptide COVID-19 Therapeutic, Dr. Michael Peters, Publishes White Paper

Hoth Therapeutics Inc (HOTH)

Company Profile

Rocket One and NASA reach agreement to advance space AI technology

Rocket One and NASA Reach Agreement to Advance Space AI Technology

Rocket One partners with Placeve to advance intelligent edge computing

Rocket One Expands AI Infrastructure Platform Through Strategic Partnership with Placeve to Advance Defense, Space, and Intelligent Edge Computing

Rocket One adds the SpaceXAI API to its AI tech stack

Rocket One Adds SpaceXAI API to Its AI Technology Stack, Advancing Next-Generation Space and Defense Computing

Rocket One regains compliance with Nasdaq listing rules

Rocket One Regains Full Nasdaq Compliance with Minimum Bid Price Requirement

Rocket One Launches Swarm Stage AI™ to Counter Autonomous Drone Swarms

Rocket One Reports Approximately $8.4 Million in Cash and Cash Equivalents and Outlines Strategy Across AI Infrastructure, Spintronic Computing for Space and Defense Markets

These space stocks are not SpaceX—but they're blasting off this week in the wake of IPO fever

ROCKET ONE APPOINTS MAJOR GENERAL MALCOLM B. FROST (RET.

Rocket One Appoints Dr. Supriyo Bandyopadhyay as Lead Technical Advisor of AI Nanomagnetic Technology

Hoth Therapeutics Becomes Rocket One Inc. (Nasdaq: RKTO), Targeting the Space Economy with Next-Generation Nanomagnetic AI Chip Technology and Ultra-Low-Power, Radiation-Tolerant Computing for Space and Defense Applications

Hoth Therapeutics Granted 180 Day Extension by Nasdaq to Regain Compliance with Bid Price Rule

Hoth Therapeutics' Scientific Advisory Board Member and Inventor of Licensed Novel Peptide COVID-19 Therapeutic, Dr. Michael Peters, Publishes White Paper